Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

490 women who used Stediril (.5 mg norgestrel and .05 mg ethinyl estradiol, combined) for a total of 5600 cycles or 466 woman-years over a 3 year period are presented. They all took the pills primairly for contraception; most were 20-30 years old, and took Stediril 3-6 months. Some other indications were 119 cases of menstrual irregularity, 15 of spaniomenorrhea, 14 of premenstrual syndrome and 3 of acne, all relieved. 46 of 50 cases of menorrhagia, 83 of 89 of dysmenorrhea and 32 of 34 with pelvic pain were relieved. Withdrawal bleeding was usually less than before and tended to diminish with time. There were 46 women with nausea, 3 of whom stopped Stediril. Migraines sometimes a ppeared, sometimes disappeared, but often occurred regularly on the first day between pill cycles. 52 women complained of breast congestion for the first time. Weight rose in 2301, fell in 98 and stayed constant in 134 after 3 months: weight was easily controlled with diet and appetite supressant drugs. No hypertension was observed. There were 19 single cycles of amenorrhea, several cases of persistant amenorrhea and 4 cases of amenorrhea after stopping. 2-3% of cycles were marked by metrorrhagia; 63 women had spotting, 8 had significant metrorrhagia; 7 had metrorrhagia followed by withdrawal bleeding in that cycle. 1 woman had a thromboembolism of the left leg after 2 pill cycles during which she gained 3 kg. There was 1 pregnancy due to irregular pill use.
 ...
PMID:[Clinical study of an estro-progestative association in low doses. Experience of 3 years (490 patients-5600 cycles)]. 426 90

It is noted that advertisements in medical journals recommend treatment of emotional symptoms in menopausal patients with Premarin (Ayerst brand of conjugated estrogens), Ogen (Abbott brand of piperazine estrone sulfate), or other compounds. There are no acceptable studies proving the usefulness of such combinations for symptoms relating to the menopause and no persuasive evidence to justify use of conjugated or any other type of estrogen in the treatment of emotional symptoms in menopausal women. Vasomotor symptoms, flushing, and sweats respond to estrogens. Symptoms do not recur if treatment is stopped after 1 or 2 years. Systematic or topical use of estrogens fails to promote the appearance of youthfulness. Vaginal pruritus and dyspareunia due to atrophic vaginitis may be relieved by estrogens either applied locally or orally. Libido is not heightened by exogenous estrogens but sufficient androgen doses cause virilization. It is doubtful if osteoporosis is favorably influenced by long-term use of estrogens. Estrogen therapy may cause spotting, menarrhagia, nausea, breast tenderness, or fluid retention. Prolonged use may cause increase in size of uterine fibroids. Personal or even family history of breast or genital cancer are considered contraindications.
 ...
PMID:Estrogens and the menopausal patient. 434 58

Ovostat, sold in Belgium as Pregnon 28 (1 mg lynestrenol and 50 mcg ethinyl estradiol) was taken by 146 women for up to 12 cycles without any pregnancies. The patients ranged in age from 17-51, and included 80 without and 66 with oral contraceptive experience. Pill cycles tended to have lighter and shorter flow, a 2-3 day latency period, and duration of 3-5 days in 90%. 25 incidents of amenorrhea were reported and 3 patients stopped because of spotting or breakthrough bleeding. 18 (12.3%) experienced nausea, 13 (8.9%) headache, 14 (9.6%) breast pain, and 19 (13%) depression or nervousness. 8 dropped out for drug-related reasons and 17 for personal reasons.
 ...
PMID:[Clinical study of a new oral contraceptive: ovostat]. 458 59

The efficacy, safety, and patient acceptance of an oral contraceptive containing 150 mcg d-norgestrel and 30 mcg ethinyl estradiol (150/30) were studied in 99 women who completed 754 cycles of medication between late 1971 and October 1973. 1 pregnancy occurred giving a pregnancy rate of 1.6 per 100 woman-years. This woman's previous history indicated unreliability in pill taking. The mean pretreatment length of menses was 4.9 days and during treatment, 4 days. Although intermenstrual bleeding and amenorrhea were noted in early cycles, there was a decrease in the usual incidence of headaches, nausea, vomiting, and depression. Results of the study and patients' acceptance suggest that the 150/30 combination may be used as the oral contraceptive of first choice.
 ...
PMID:Clinical assessment of a low-dose oestrogen, low-dose progestogen combined oral contraceptive. 482 25

The effects of large doses of ethinyl estradiol on implantation and early gestation in women were evaluated. 32 women exhibiting early amenorrhea were treated with a daily dose of 1 mg of ethinyl estradiol for 7 consecutive days. It was determined through testing that 12 of the women were not pregnant. In 14 of the 20 pregnant women, side effects were noted in the form of nausea and vomiting. Histologic examination of the endometrial specimens indicated the presence of placental tissue in all subjects. It was considered possible that the dose of ethinyl estradiol administered might be insufficient to induce abortion. In a second study, a dose of 5 mg was administered daily for 7 days to a group of 6 women. The beginning of estrogen treatment varied between 36 and 46 days. Nausea was milder in this group than in the subjects treated with only 1 mg of ethinyl estradiol. Abortion did not occur. In a third study, 4 fertile women with approximately normal cycles were given daily doses of 5 mg of ethinyl estradiol from the twenty-first to the twenty-eighth day of the cycle during 2 cycles. 3 of the 4 subjects became pregnant. It was concluded that ethinyl estradiol is not a reliable abortifacient in women and that its efficiency as a postcoital contraceptive may be limited to a relatively short period following ovulation and prior to implantation.
 ...
PMID:Failure of large doses of ethinyl estradiol to interfere with early embryonic development in the human species. 542 72

100 patients of a private gynecologic practice took Planovine (4 mg megestrol acetate 50 mcg ethinyl estradiol) for 1-26 cycles, starting in 1968. The group was composed of 17 nulliparas, 57 who had 1-3 abortions, 69 taking Planovine for various gynecologic indications, and 40 using contraception for the 1st time. The menstrual flow was usually the same, but diminished in 19 women, became more regular in 10 women, but intermenstrual bleeding occurred in 18 women during 1 to 7 cycles. 38 gynecologic disorders were improved. Side effects included nausea or stomach pain (15 cases), weight gain (27), weight loss (40), headache (5), and nervous complaints (11). Although 15 women initially had mild venous disorders such as swollen veins, heavy limbs, and varicosities, no further circulatory complications appeared. 19 representative endometrial biopsies are described.
 ...
PMID:[Clinical study of Planovine in gynecologic practice]. 556 16

To study the safety and efficacy of a norgestrel-ethinyl estradol oral contraceptive compound, 300 Mexican women, 16-42 years of age were orally administered .5 mg norgestrel and .05 mg ethinyl estradiol (Ovral) daily over a total of 3175 study cycles. Most of the women were poor., uneducated and of high parity. None of the patients in the study became pregnant, even in the cycles where 1 or more doses were omitted. The menstrual cycle remained basically unaltered with breakthrough bleeding or spotting sometimes reported, usually when doses were missed. Unexplained amenorrhea occurred in 1.2% of the cycles. Though 5% of the women were ovulatory at one time of another as determined by pregnandiol levels, no pregnancy resulted, which is probably explained by changes in the cervical mucus caused by the pills making an inhospitable environment for sperm migration. Psychosomatic-related side-effects included nausea, headache and decreased libido in less than 1% of the cycles. Chloasma aggravated by poor dietary intake occurred in .5% of the cycles. No malignant, peripheral vascular or other serious disease occurred during the treatment and no significant endometrial alterations were seen.
 ...
PMID:Norgestrel and ethynyl estradiol: a new low-dosage oral agent for fertility control. 563 91

264 women (about 50% private patients), all less than 40 years old and none with history contraindicating oral contraception, were started on a regimen with Ovral (.5 mg norgestrel and .05 mg ethinyl estradiol). Medication started on Day 5 of a menstrual cycle. Then therapy followed a 3 weeks on, 7 days off schedule. Patients continued for 1-22 cycles (mean 7 cycles) for a total of 1918 cycles. Despite the omission of 42 doses by 32 patients, no pregnancies occurred. The percentages of cycles with average flow, spotting, breakthrough bleeding, and dysmenorrhea were 74.4, 2.5, .4, and .6, respectively. The incidence of amenorrhea, .2%, was spectacularly low in comparison with findings in other studies. Papanicolaou smears (483) were all normal (Class I or II). Morphologic changes seen at endometrial biopsy (61) were similar to those produced by other available progestogen-estrogen compounds. No significant variation from control findings (1878) were found in 1463 laboratory studies. The studies included leukocyte and differential counts (724), and determinations of hemoglobin and hematocrit (388), fasting blood sugar and blood urea nitrogen (114), bilirubin and liver function (61), and renal function (176). Minor symptoms (nausea, vomiting, headache, etc.) were few and disappeared after the first few cycles. The preparation suppresses ovulation (probably through action of the estrogen), probably alters the cervical mucus to inhibit sperm penetration, possibly interferes with nidation, and may interfere with follicular development.
 ...
PMID:Norgestrel, a low dose, oral progestogen for fertility contro. Supplementary report. 564 94

Effects of a new low-dosage combination oral contraceptive containing .5 mg WY3707 (a progestational substance) plus .05 mg ethinyl estradiol were studied on 30 normal women. Findings based on 25 patients remaining in the study for 5 months indicate a weight gain (64%), a tendency to hypo- and oligomenorrhea (58.3%), headache (52%), dizziness (44%) and nausea (20%) as common side-effects. Blood pressure recordings were below 140/90 and had no major variations. Blood sodium and potassium levels, measured before therapy initiation and 2 and 5 months after use, showed no significant changes. Discussion centers on 20 previous studies relating oral contraceptives to blood electrolytes and pressure and weight and menstrual changes.
 ...
PMID:Effect of a new low-dosage oral contraceptive pill on blood electrolytes. A combined clinical and laboratory evaluation. 576 88

Evaluation of a new sequential oral contraceptive, 16 tablets of .1 mg ethinyl estradiol plus 5 tablets of .1 mg ethinyl estradiol and 5 mg compound with a structure similar to to progesterone. 74 patients dropped out, 18 of the 32 did not respond to personal communications; of the remaining 14 who discontinued the medication, 4 became pregnant but not from failure of the pill, 5 left because of nausea, and 5 left for personal reasons. There was a total of 515 completed cycles. Nausea occurred in 14.8% of the cycles with a marked decrease after the first cycle; breast soreness occurred in 5.8% of the cycles, intermenstrual bleeding and spotting in 6.4% of the cycles. The endometrium showed no adverse effects, and except for shortened bleeding times, no significant changes in laboratory values, including clotting mechanisms, were noted.
 ...
PMID:Evaluation of megestrol acetate and ethinyl estradiol as an oral contraceptive. 607 34


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>